Medicines, Poisons and Therapeutic Goods Regulation 2008

The following are the additional requirements for supplying a controlled medicine for human use during a consultation:

the prescriber has a controlled medicines approval to prescribe the medicine;

Note For controlled medicines approvals, see pt 13.1.

if the approval is for a particular form of the medicine—the supply is for the form of the medicine approved or a bioequivalent form;

Note Bioequivalent—see the dictionary.

if the approval is for a particular strength of the medicine—the supply is for the strength approved or a weaker strength;

if the approval is for a maximum daily dose of the medicine—the supply is for not more than the maximum daily dose approved;

the prescriber complies with each condition (if any) of the approval.

Example—par (b)

If a slow release form of a medicine is approved, the prescriber is not authorised to prescribe an immediate release form of the medicine.

164 Information for CHO about monitored medicines supplied during consultations—Act, s 31 (2) (b) and (4), def required information

This section applies if a prescriber supplies a monitored medicine for human use during a consultation.

Note Supply does not include administer (see Act, s 24).

The prescriber must, not later than 7 days after the end of the month when the monitored medicine is supplied, give the chief health officer the following information in writing:

the prescriber’s name, business address and telephone number;

the name, date of birth and address of the person to whom the medicine is supplied;

the date of supply;

the monitored medicine, and the form, strength and quantity of the medicine, supplied.

Division 4.2.7 Selling pseudoephedrine by retail